← Leaderboards
Eric Daniel Eisenmann
Ohio State University
$650,329
Attributed
$650,329
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $601.1K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$650,329 · 2
By mechanism
R37$601,091 · 1
F31$49,238 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Electra D. Paskett$38,729,537
- David P Carbone$20,647,321
- Chyke Abadama Doubeni$16,866,019
- Nilsa Del Carmen Ramirez$84,826,096
- Patricia A. Ganz$11,268,092
Others in their field
Other Emerging Leaders on “Toxic Effect”
- Matthew Johnson · Duke University$56,071,536
- John Damon Chodera · Sloan-Kettering Inst Can Research$25,853,758
- Kristin Aillon · Midwest Research Institute$24,228,962
- Bronwen Shaw · Medical College Of Wisconsin$19,182,557
- Xinhua Li · Nano Terra, Inc.$17,491,533
- Thomas Denny · Duke University$16,626,143
Research focus
Toxic EffectAdverse EventPreventTumorPropertyIn VitroMouse ModelPharmacokinetics And PharmacodynamicsSide EffectDrug KineticsProspectiveDosePharmaceutical PreparationsAntineoplastic AgentsB Lymphoid MalignancyBiological AvailabilityAnticancer ActivityAdverse EffectsDoctor Of PhilosophyDrug Metabolism InhibitionB Cell ProliferationCancer CellCyp3a4 GeneCollege
Grant awards (3)
Damage-associated molecular patterns in chemotherapy toxicity$601,091
R37 · FY2025 · CA · contact PI
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition$15,692
F31 · FY2021 · CA · contact PI
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition$33,546
F31 · FY2020 · CA · contact PI